Evaluating Safety and Effects of GSK5926371 in Adults With B-cell Driven Autoimmune Rheumatic Diseases

What this Trial Is About

Researchers are studying GSK5926371 in adults with autoimmune rheumatic diseases, including systemic lupus erythematosus, rheumatoid arthritis, idiopathic inflammatory myopathies, and Sjogrens disease. The trial aims to evaluate the safety, tolerability, how the body processes the drug, its effects, and any immune responses it may trigger. This is a Phase 1 interventional study sponsored by GlaxoSmithKline. The study has two parts Part 1 involves dose escalation to find a suitable priming dose of GSK5926371. In Part 2, participants receive doses based on findings from Part 1. GSK5926371 is administered as the investigational treatment throughout the study. The design is sequential, with dosing and evaluations adjusted according to initial results. Participants will be involved in clinic visits for drug administration, safety monitoring, and various assessments over up to 196 days. These include tracking adverse events, measuring drug levels in the blood, evaluating immune cell counts, antibody responses to the drug, immunoglobulin levels, vital signs, laboratory tests, and electrocardiograms. The study monitors participants closely to understand the drugs impact and safety profile.

A Study of GSK5926371 in Participants With B-cell Driven Autoimmune Rheumatic Diseases (ARD)